Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 7/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | KYAT1 | Q16773 | 6/20 | 0.50 |
| ▸ | DHODH | Q02127 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10479612 | 1.00 | GAA (0.62) | GAALMNAALDH1A1NPSR1HPGD | |
| SCHEMBL10479609 | 1.00 | GAA (0.62) | GAALMNAALDH1A1NPSR1HPGD | |
| SCHEMBL10479460 | 0.86 | KYAT1 (0.62) | GAALMNAALDH1A1NPSR1HPGD | |
| SCHEMBL4104434 | 0.85 | MEN1 (0.62) | GAALMNAALDH1A1NPSR1HPGD | |
| SCHEMBL10479779 | 0.85 | MAPT (0.57) | GAALMNAALDH1A1NPSR1HPGD | |
| SCHEMBL13664219 | 0.85 | MAPT (0.57) | GAALMNAALDH1A1NPSR1HPGD | |
| SCHEMBL10479594 | 0.85 | MAPT (0.57) | GAALMNAALDH1A1NPSR1HPGD | |
| SCHEMBL13901610 | 0.84 | GAA (0.62) | GAALMNAALDH1A1NPSR1HPGD | |
| SCHEMBL9881210 | 0.84 | GAA (0.62) | GAALMNAALDH1A1NPSR1HPGD | |
| SCHEMBL13901608 | 0.83 | GAA (0.63) | GAALMNAALDH1A1NPSR1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253673-A1 | Substituted Pyrazoles as Ghrelin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-10-08 | — | — | US | disclosed |
| US-20090253673-A1 | Substituted Pyrazoles as Ghrelin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253673-A1 | Substituted Pyrazoles as Ghrelin Receptor Antagonists | GIPR, GPR119, GLP1R | GAA 2005/4885LMNA 4188/4885ALDH1A1 3415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.